Inclusion Criteria Each participant must meet the following criteria to be enrolled in
this study.

1. At least aged 18 years old at the time of consent.

2. If female, be surgically sterile or post-menopausal (no menses for at least 12
months), or if of childbearing potential, must be using an acceptable method of
contraception such as a combination estrogen/progestin hormonal contraceptive (oral
or injected) for at least 1 month prior to Day 1, or such items as an IUD,
intrauterine system (IUS), transdermal hormonal implant, vaginal hormonal ring, or 2
forms of the following: diaphragm, cervical cap, patch, condom, spermicide, or
sponge. Total abstinence is permitted. If local regulations deviate from the
previously listed contraception methods to prevent pregnancy, local requirements
will apply. In addition, females of childbearing potential must agree to continue to
use their method of birth control for the duration of the study and 12 weeks
following discharge from the study.

3. If male, be surgically sterile, or agree to use appropriate contraception (latex
condom with spermicide) when engaging in sexual activity and agree to not donate
sperm for the duration of the study and 12 weeks following discharge from the study.

4. Be in good health (ie, no acute illnesses or hospitalizations within 30 days of the
study start, no planned procedures during study participation, and no newly
diagnosed chronic illnesses that are not deemed stable by the participant's primary
care physician), in the opinion of the Investigator, based on medical history (ie,
absence of any clinically relevant abnormality) during Screening.

5. Be able to understand and provide written, informed consent.

6. Access to a telephone, the internet, a device that reliability connects to the
internet, and able to dial into telehealth checkups and study-related assessments.
If access to the internet precludes involvement, then paper diaries may be completed
and promptly entered into the data capture system at the study centers as part of
the regular follow-up visits.

7. Must be able to receive study product shipments directly to their home (ie, no Post
Office Boxes), unless in a region (EU) or other location where the participant must
receive the study product directly from the sites' staff/physician.

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the study.

1. Participants with acute illnesses or hospitalizations within 30 days of the study
start, and/or planned procedures during study participation, and/or newly diagnosed
chronic illnesses that are not deemed stable by the participant's primary care
physician), based on Investigator assessment of medical history during Screening.

2. Participants with any respiratory infection, flu-like symptoms, or unexplained fever
or chills during the week prior to Screening (see Section 6.6.2).

3. Participants with any prior history of SARS-CoV-2 infection.

4. Participants who use intranasally dosed drugs, prescriptions or over-the-counter
medications such as fluticasone within the last 7 days.

5. Participants who underwent a previous tracheostomy.

6. Participants who are receiving any form of oxygen therapy.

7. Females who are breastfeeding, pregnant, or attempting to become pregnant.

8. Participants who have any other condition that, in the opinion of the Investigator,
would interfere with a participant's ability to adhere to the protocol (eg,
participants whom are mentally or neurologically disabled and whom are considered
not fit to their participation in the study), interfere with assessment of the
investigational product, or compromise the safety of the participant or the quality
of the data.